Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. PCAS
  6. News
  7. Summary
    PCA   FR0000053514

PCAS

(PCA)
  Report
Real-time Euronext Paris  -  10:23 2022-09-29 am EDT
7.520 EUR   +0.27%
09/081st HALF 2022 EARNINGS REPORT
GL
09/081st HALF 2022 EARNINGS REPORT
GL
09/08PCAS : 1st-half-year results
CO
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Pcas: Release of the 2021 Universal Registration Document (URD)

04/29/2022 | 12:07pm EDT

RELEASE OF THE 2021 UNIVERSAL REGISTRATION DOCUMENT (URD)

Ecully, April 29, 2022

The PCAS Universal Registration Document 2021, which includes the annual financial report, was filed with France's Financial Markets Authority, in ESEF format (European Single Electronic Format), on April 29, 2022, under number D.22-0386.

This document contains:

  • The 2021 annual financial report

  • The Board of Directors' corporate governance report in accordance with Section L.225-37 of France's Commercial Code

  • Information on the statutory auditors' fees

This document is now available:

  • At PCAS headquarters: 21 chemin de la Sauvegarde, 21 Ecully Parc, CS 33167, 69134 Ecully, France
  • On the company website: www.pcas.com
 NEXT FINANCIAL DISCLOSURE:
2021 Shareholder’s Meeting in Ecully at 10 a.m. on June 9, 2022

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With about 12% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €187.0 million in 2021 and employs nearly 1200 people in six countries.

To find out more about PCAS: www.pcas.com

PCASNewcap
Philippe Clavel / Eric Moissenot

Emmanuel Huynh / Louis-Victor Delouvrier
Financial communication and investor relations
Tél. : +33 1 69 79 60 00
www.pcas.com
Tél. : +33 1 44 71 98 53
pcas@newcap.eu

Attachment


All news about PCAS
09/081st HALF 2022 EARNINGS REPORT
GL
09/081st HALF 2022 EARNINGS REPORT
GL
09/08PCAS : 1st-half-year results
CO
07/29Pcas : Net sales as of june 30, 2022
GL
07/29PCAS SA Provides Consolidated Earnings Guidance for the First Half of 2022
CI
07/29PCAS SA Reports Consolidated Sales Results as of June 30, 2022
CI
07/29Pcas : Net sales as of june 30, 2022
GL
07/29PCAS : 2nd quarter earnings
CO
05/13Pcas : Net sales as of march 31, 2022
GL
05/13Pcas : Net sales as of march 31, 2022
GL
More news
Financials
Sales 2021 187 M - -
Net income 2021 -40,5 M - -
Net Debt 2021 62,2 M - -
P/E ratio 2021 -2,85x
Yield 2021 -
Capitalization 103 M 101 M -
EV / Sales 2020 1,05x
EV / Sales 2021 0,95x
Nbr of Employees 1 092
Free-Float 14,1%
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Philippe Clavel Chief Executive Officer
Eric Moissenot General Director-Finance & Administration
Pierre Luzeau Chairman
Gérard Guillamot Scientific Director
Jacqueline Lecourtier Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PCAS-10.48%101
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296